Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00655837 · ClinicalTrials.gov registry record · Phase 1
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
A Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, Large B-Cell, Diffuse, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 9
- Study locations
NCT00655837 is a Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, Large B-Cell, Diffuse that has completed, run by Seagen. The registered enrollment target is 33 participants, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (92% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT00655837, a Phase 1 study of Lymphoma, Non-Hodgkin and Lymphoma, Large B-Cell, Diffuse, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma. This study is also intended to estimate how well your disease responds to this treatment.
Conditions Studied
Interventions
- DRUG gemcitabine
- DRUG rituximab
- DRUG SGN-40
Study Locations (9)
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Arizona - Scottsdale
Colorado
- University of Colorado - Aurora
Illinois
- Oncology Specialists - Park Ridge
Missouri
- Washington University School of Medicine - St Louis
Nevada
- Nevada Cancer Institute - Las Vegas
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00655837
The ClinicalTrials.gov registry entry for NCT00655837 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 394-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (92% lower). The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 3 interventions - of which gemcitabine is the first listed.
NCT00655837 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Alabama, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00655837 about?
NCT00655837 is a clinical study titled "Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL". The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma. This study is also intended to estimate how well your disease responds to this treatment.
What is the current status of trial NCT00655837?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2008-04. Estimated completion is 2010-02.
What conditions does trial NCT00655837 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse.
What interventions are being tested in trial NCT00655837?
The interventions under investigation include: gemcitabine (DRUG), rituximab (DRUG), SGN-40 (DRUG).
Who is sponsoring clinical trial NCT00655837?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00655837 being conducted?
This trial has 9 study locations across Alabama, Arizona, Colorado, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
-
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.